Endpoint
HDL cholesterol
Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including cholesterol esters and free cholesterol.
CAT:outcome/hdl-cholesterolreported in mg/dL37 findings from 22 compounds
What moved it
How to read these marks37 findings · 22 compounds · 25 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| resveratrol | no effect | 3 | Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. |
| curcumin | up 2 · no effect 5 | 7 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| magnesium(2+) | up 2 · no effect 1 · down 1 | 4 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| melatonin | up 1 · no effect 1 | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| (R)-carnitine | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Lactiplantibacillus plantarum | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| lipoic acid | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| nicotinamide | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| NMN zwitterion | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| taurine | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| vitamin D2 | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| Zn(2+) | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| chromium(3+) | no effect | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
| coenzyme Q10 | no effect | 4 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| astaxanthin | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| berberine | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| Camellia sinensis | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| crocin-1 | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| L-arginine | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| naringenin | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| α-tocopherol | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| pectin | up | 1 | Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited. |
Reported to move it
12 findings
melatonin — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“HDL-C levels were substantially increased (WMD: 2.04 mg/dL, 95% CI: 0.50, 3.57) following melatonin supplementation.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect 2.04 mean difference, 95% CI 0.5 to 3.57
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249Permalink
curcumin — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Furthermore, at the end of the study, the Curcumin group reported lower LDL levels ( P = 0.024) and higher HDL levels ( P = 0.024) versus the control group.”
Quoted verbatim from Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.. - Study
- RCT
- Dose
- Oral Puritan's Pride Turmeric Curcumin 500 mg capsules (Curcuma longa root 450 mg plus turmeric extract 50 mg standardised to 95% curcuminoids), one capsule three times daily after meals (1500 mg/day) for 14 weeks, added to conventional therapy
- Population
- Adults aged 50-74 y with type 2 diabetes and a 10-year ASCVD risk score >=5%, Cairo, Egypt; 85 randomised (42 curcumin, 43 control), 72 analysed (36 per group); open-label trial in which the control arm received conventional therapy only, with no placebo; the paper declares no primary endpoint and powered its sample size on change in HDL-C; LDL-C calculated by the Friedewald equation, HDL-C by enzymatic colorimetric assay
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.2025PMID:40759997Permalink
nicotinamide — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Mean HDL concentrations increased in the NAMR group, resulting in significant differences between the treatment groups at weeks 12, 24 and 52.”
Quoted verbatim from Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- modified-release nicotinamide 250-1500 mg/day (one to six 250 mg capsules once daily before bed)
- Population
- Adults on maintenance haemodialysis with hyperphosphataemia, modified-release nicotinamide versus placebo, both arms on their individual phosphate binders
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.2023PMID:35751625Industry fundedPermalink
vitamin D2 — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A).”
Quoted verbatim from Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 4 months
- Dose
- 100,000 IU ergocalciferol (vitamin D2) orally once monthly for 4 months
- Population
- Adults aged 30-75 at elevated risk of type 2 diabetes (non-diabetic hyperglycaemia or positive diabetes risk score), UK; vitamin D2 arm versus placebo arm
Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.2016PMID:26700109Industry fundedPermalink
magnesium(2+) — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Those who received magnesium supplementation had significantly higher levels of HDL-cholesterol compared to the placebo group at the end of the study (49.7 ± 10.9 vs 43.6 ± 7.2 mg/dL, P = 0.003; estimated statistical power 0.90).”
Quoted verbatim from Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 250 mg magnesium as magnesium oxide tablet once daily
- Population
- People with prediabetes aged 18 to 65 in Isfahan, Iran, 12-week double-blind placebo-controlled trial; 71 completers (34 magnesium, 37 placebo)
Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.2022PMID:36307427Permalink
astaxanthin — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“In summary, our systematic review and meta-analysis revealed that astaxanthin consumption was associated with increase in HDL-C and decrease in CRP.”
Quoted verbatim from The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- adults; meta-analysis of randomized controlled trials of astaxanthin supplementation (14 studies)
The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.2020PMID:32755613Permalink
Show the remaining 6
magnesium(2+) — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36] but had no effect on total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride.”
Quoted verbatim from Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.. - Study
- meta-analysis
- Dose
- 15 mmol/day (360 mg/day) oral magnesium, median
- Population
- Adults with type 2 diabetes in randomized double-blind controlled trials of oral magnesium supplementation
Effect 0.08 mean difference, 95% CI 0.03 to 0.14
Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.2006PMID:16978367Permalink
naringenin — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Naringenin consumption significantly reduced percentages of NAFLD grades (P < .001), as well as, serum levels of triglyceride (TG) (P < .001), total cholesterol (TC) (P = .01), and low-density lipoprotein (LDL) (P = .02) and increased serum level of high-density lipoprotein (HDL) (P = .02) compared with the control group.”
Quoted verbatim from Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 100 mg capsules twice a day, before lunch and dinner
- Population
- 44 overweight/obese patients with NAFLD, placebo-controlled
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.2021PMID:34516703Permalink
berberine — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001).”
Quoted verbatim from Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- patients with dyslipidaemias
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.2018PMID:30466986Permalink
curcumin — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Beyond that, Curcumin intake significantly increased high-density lipoprotein cholesterol (HDL-C) levels (ES: 1.34 mg/dl, 95% CI: 0.37, 2.31, p = 0.007; I2 = 97.8%, p < 0.001).”
Quoted verbatim from Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis.. - Study
- meta-analysis
- Population
- adults, umbrella meta-analysis of 19 meta-analyses
Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis.2022PMID:36058763Permalink
magnesium(2+) — decreases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“HDL-cholesterol was significantly lower after magnesium compared with placebo (1.14±0.08 vs 1.20±0.09 mmol/l, p=0.026), but no effect on total cholesterol, LDL-cholesterol and triglycerides was found (Table 2).”
Quoted verbatim from Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.. - Study
- crossover
- Participants
- 14
- Duration
- 6 weeks
- Dose
- 15 mmol magnesium per day (360 mg) as magnesium gluconate liquid, 50 ml three times daily, for 6 weeks
- Population
- Adults with insulin-treated type 2 diabetes and serum magnesium at or below 0.79 mmol/l, 14 participants
Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.2024PMID:37922013Permalink
pectin — increases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“In pigs fed with pectin, total cholesterol and low-density lipoprotein cholesterol (LDL-C) were lowered but high-density lipoprotein (HDL-C) was increased (P < 0.05).”
Quoted verbatim from Effects of dietary pectin on the profile and transport of intestinal bile acids in young pigs.. - Study
- animal · not in humans
- Duration
- 2 months
- Dose
- 5% pectin in diet
- Population
- Young pigs fed corn-soybean meal diets with 5% pectin or cornstarch control for 72 days
Effects of dietary pectin on the profile and transport of intestinal bile acids in young pigs.2018PMID:30102377Permalink
Measured, no effect detected
25 findings
resveratrol — no detected effect on
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull resultreplicated ×2“The pooled effect estimate revealed no effect of resveratrol on HDL (MD = 0.24; 95% CI [-3.53, 4.00], P = 0.90).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Participants
- 108
- Population
- Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect 0.24 mean difference, 95% CI -3.53 to 4
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
resveratrol — no detected effect on
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull resultreplicated ×2“Compared with the placebo, resveratrol did not improve HDL-C levels (WMD: −1.05 mg/dL, 95% CI: −2.44, 0.33; P=0.14;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 837
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; secondary endpoint, 14 pooled RCTs, resveratrol vs placebo
Effect -1.05 mean difference, 95% CI -2.44 to 0.33
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602Permalink
Zn(2+) — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There was no effect of zinc supplementation on HDL cholesterol for either low- or high-dose supplementation.”
Quoted verbatim from Effects of Dose and Duration of Zinc Interventions on Risk Factors for Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- up to 75 mg/d elemental zinc; low <25 mg/d and high >=25 mg/d strata
- Population
- Participants (healthy, obese, type 2 diabetes, prediabetes, haemodialysis and other groups, children to older adults) in randomised trials of zinc supplements up to 75 mg/d versus placebo or control, pooled within low-dose and high-dose strata
Effects of Dose and Duration of Zinc Interventions on Risk Factors for Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta-Analysis.2021PMID:32722790Industry fundedPermalink
curcumin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×4“However, the pooled effects of curcumin supplementation on LDL, HDL, and TG were not statistically significant regardless of its forms, see Supplementary Appendix S–U.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.. - Study
- meta-analysis
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD/NASH); additional (non-liver-enzyme) outcome of the updated meta-analysis, pooled across 10 trials
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
lipoic acid — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 300 to 1800 mg/day across trials
- Population
- Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
(R)-carnitine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“However, plasma HDL-C (WMD: 0.85 mg/dL, 95% CI: −2.34, 4.05, p = 0.601) and triglycerides (WMD: −2.42 mg/dL, 95% CI: −34.85, 30.01, p = 0.884) were not altered by L-carnitine.”
Quoted verbatim from Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 1 g 3 times per week to 4 g/day across included trials; 1 to 24 weeks
- Population
- Adults in 6 treatment arms of randomised trials (intravenous and oral L-carnitine pooled) reporting HDL-C, versus control
Effect 0.85 mean difference, 95% CI -2.34 to 4.05
Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials.2016PMID:26754058Industry fundedPermalink
Show the remaining 19
Lactiplantibacillus plantarum — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Throughout the 24-week intervention, lipid profiles, including total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol, remained stable and within normal reference ranges in both the placebo and probiotic groups, with no statistically significant differences observed between groups (Table 3).”
Quoted verbatim from Safety of Lactiplantibacillus plantarum K014 in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.. - Study
- RCT
- Duration
- 6 months
- Dose
- one sachet daily, at least 1 x 10^9 CFU L. plantarum K014 with 2 g maltodextrin, for 24 weeks
- Population
- Healthy Malaysian adults aged 18 and over; whole 24-week intervention; maltodextrin placebo in the comparator arm
Safety of Lactiplantibacillus plantarum K014 in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.2026PMID:42124006Permalink
NMN zwitterion — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Regarding lipid indicators, NMN supplementation had no significant effect on HDL-C, LDL-C, total cholesterol, or triglycerides.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 250-2000 mg/day oral across included trials
- Population
- Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
taurine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect 0.644 mean difference, 95% CI -0.244 to 1.532
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
chromium(3+) — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“Six months of chromium supplementation (500 mcg or 1000 mcg) was not associated with any significant changes in glycohemoglobin, weight, waist circumference, BMI, blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, or urine microalbumin compared with placebo.”
Quoted verbatim from Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.. - Study
- crossover
- Duration
- 6 months
- Dose
- chromium picolinate 500 mcg or 1000 mcg daily
- Population
- Adults with impaired glucose tolerance, impaired fasting glucose or metabolic syndrome, without diabetes; modified cross-over, 6 months of chromium picolinate versus placebo
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.2011PMID:20634174Industry fundedPermalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“Plasma HDL-cholesterol and TG concentrations remained unchanged across all groups.”
Quoted verbatim from Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 200 mg/day
- Population
- hypercholesterolaemic adults; 2×2 factorial trial (placebo, phytosterols 2 g/d, curcumin 200 mg/d, or phytosterols+curcumin combined), result reported across all four trial arms
Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.2018PMID:29291429Permalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“However, curcuminoids were not found to affect serum levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (p > 0.05).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- 1 g/day for 30 days
- Population
- obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“The trial showed no evidence of effect of CoQ10 supplementation on total cholesterol (MD 0.30 mmol/L, 95% CI -0.10 to 0.70), high-density lipoprotein (HDL)-cholesterol (MD 0.02 mmol/L, 95% CI -0.13 to 0.17) or triglycerides (MD 0.05 mmol/L, 95% CI -0.42 to 0.52).”
Quoted verbatim from Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.. - Study
- RCT
- Population
- adults at high risk of cardiovascular disease without a diagnosis of CVD; single RCT (51 patients randomised)
Effect 0.02 mean difference, 95% CI -0.13 to 0.17
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.2014PMID:25474484Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation.”
Quoted verbatim from The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with chronic kidney disease (CKD)
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2018PMID:30417782Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“The pooled results indicated that CoQ10 supplementation had no effects on total cholesterol, or LDL-cholesterol, or on HDL-cholesterol, and triglycerides.”
Quoted verbatim from A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease.. - Study
- meta-analysis
- Population
- adults with chronic kidney disease (CKD); meta-analysis of 12 studies (17 publications)
A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease.2022PMID:33782820Permalink
magnesium(2+) — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“However, our results revealed that Mg supplementation did not have any effect on triglycerides (TG), total cholesterol (TC), and high-density lipoprotein (HDL) serum concentrations among T2DM patients in comparison with the control group.”
Quoted verbatim from The Effects of Magnesium Supplementation on Lipid Profile Among Type 2 Diabetes Patients: a Systematic Review and Meta-analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- Type 2 diabetes mellitus patients
The Effects of Magnesium Supplementation on Lipid Profile Among Type 2 Diabetes Patients: a Systematic Review and Meta-analysis of Randomized Controlled Trials.2021PMID:32468224Permalink
α-tocopherol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“The pooled analysis of 12 RCTs showed that vitamin E in patients with MASLD significantly reduced TG (-12.74 mg/dL, 95% CI: [-22.78, -2.70], p = 0.013), whereas no significant change was observed in TC (-2.11 mg/dL, 95% CI: [-4.89, 0.67], p = 0.137) and LDL-C (-5.32 mg/dL, 95% CI: [-11.15, 0.51], p = 0.074), HDL-C levels (0.23 mg/dL, 95% CI: [-0.48, 0.94], p = 0.527), and BMI (0.36 kg/m2, 95% CI: [-0.86, 1.58], p = 0.563).”
Quoted verbatim from Efficacy of Vitamin E on Lipid Profile in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Adults with metabolic dysfunction-associated steatotic liver disease (MASLD); pooled analysis of 12 randomised controlled trials
Efficacy of Vitamin E on Lipid Profile in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42092748Permalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.. - Study
- meta-analysis
- Population
- adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
crocin-1 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels.”
Quoted verbatim from The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.. - Study
- meta-analysis
- Population
- Participants in eight clinical trials of crocin supplementation (nine effect sizes), pooled
The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.2020PMID:32951748Permalink
L-arginine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Compared with the Placebo groups, there was no significant effect on low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-c) after L-Arginine treatment.”
Quoted verbatim from Effect of L-Arginine supplementation on lipid profiles and inflammatory markers: A systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- humans
Effect of L-Arginine supplementation on lipid profiles and inflammatory markers: A systematic review and meta-analysis of randomized controlled trials.2019PMID:31442577Permalink
Camellia sinensis — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“The intake of green tea did not significantly influence HDL-cholesterol, triglyceride, and Apo-B levels.”
Quoted verbatim from Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias.. - Study
- crossover
- Duration
- 8 weeks
- Dose
- 250-mg green tea dry extract capsules
- Population
- Adults aged 21-71 with dyslipidemias; low-fat background diet; crossover design
Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias.2009PMID:19838489Permalink
melatonin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“No significant effect of melatonin on high density lipoprotein cholesterol (HDL-C) and anthropometric indices was found.”
Quoted verbatim from The effect of melatonin supplementation on lipid profile and anthropometric indices: A systematic review and meta-analysis of clinical trials.. - Study
- meta-analysis
- Dose
- 0.8-30 mg
- Population
- Adults enrolled in 12 RCTs of melatonin supplementation for dyslipidaemia and anthropometric indices (641 participants total)
The effect of melatonin supplementation on lipid profile and anthropometric indices: A systematic review and meta-analysis of clinical trials.2019PMID:31235113Permalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×4“We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Population
- patients with metabolic syndrome (MetS) and related disorders
Effect 0.28 standardised mean difference, 95% CI -0.22 to 0.77
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×3“In addition, CoQ10, alone or in combination with fenofibrate, did not alter LDL-C, HDL-C and blood pressure.”
Quoted verbatim from Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- patients with diabetes; pooled across CoQ10 monotherapy and CoQ10 plus fenofibrate trials
Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis.2015PMID:25913756Permalink
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2“Also, the two groups showed no significant differences in diastolic blood pressure (DBP), HDL, or oxidative stress markers.”
Quoted verbatim from Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients.. - Study
- RCT
- Duration
- 2 months
- Population
- patients undergoing coronary artery bypass grafting (CABG)
Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients.2025PMID:40676400Permalink
How it is measured
Serum or plasma high-density-lipoprotein cholesterol concentration by direct clinical assay, either a precipitation method or a homogeneous method. The method is recorded with each finding.
Measured, not recorded
- Subject
- hdl cholesterol
- Measurements
- 111 measurements
- Recorded as a finding
- No
Show what was measured
HDL cholesterol
increases
For HDL cholesterol level, there was also a trend that the lower the dose of curcumin, the higher the effect of increase in HDL cholesterol level.
PMID:19151449 · both readings recorded this
HDL cholesterol
increases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · both readings recorded this
HDL cholesterol
no effect, WMD 1.71 mg/dL (95% CI -0.63 to 4.04)
However, no significant overall change was observed in HDL (WMD: 1.71 mg/dL; 95% CI − 0.63 to 4.04; I2 = 99.95%) and TG (WMD: − 9.28 mg/dL; 95% CI − 20.76 to 2.20; I2 = 100%).
PMID:41555409 · both readings recorded this
HDL cholesterol
increases
Magnesium supplementation increased on high-density lipoprotein (HDL) cholesterol levels [0.08 mmol/l (95% CI, 0.03 to 0.14); P for heterogeneity = 0.36]
PMID:16978367 · one of two readings recorded this
HDL cholesterol
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
HDL cholesterol
no effect
DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not
PMID:21975919 · one of two readings recorded this
HDL cholesterol
increases
DHA also raised high-density lipoprotein (4.49 mg/dL; 95% CI, 3.50–5.48) compared with placebo, whereas EPA did not
PMID:21975919 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.742
HDL cholesterol, mmol/L | 25 | 1.4 (0.51) | 23 | 1.4 (0.44) | 12 | 1.3 (0.25) | 13 | 1.1 (0.28) |.742 |.182 |.232
PMID:22237883 · one of two readings recorded this
HDL cholesterol
decreases
HDL-C (mg/dL) | 77.13 | ± | 3.55 | 63.25** | ± | 3.04 | 54.47§§ | ± | 2.73 | 41.45**§§ | ± | 2.23
PMID:22509243 · one of two readings recorded this
HDL cholesterol
increases, p = 0.044, n = 23
LDL (p = 0.035), glucose (p = 0.043), Fe (p = 0.048), and significant increase in HDL (p = 0.044), TAS (p = 0.036), Zn (p = 0.037), and Mg (p = 0.047)
PMID:22581111 · one of two readings recorded this
HDL cholesterol
no effect, n = 46
HDL (mmol/L) | 1.12 ± 0.24 | 1.09 ± 0.25 | NS | 1.28 ± 0.26* | 1.15 ± 0.21 | NS
PMID:22581111 · one of two readings recorded this
HDL cholesterol
no effect
High density lipoprotein cholesterol cholesterol (mmol/L) | 9 | 2031 | 0 | −0.01 (−0.03 to 0.00)
PMID:23558163 · one of two readings recorded this
HDL cholesterol
no effect
The HDL-cholesterol level was elevated slightly but not significantly during ingestion of chromium picolinate
PMID:2408233 · one of two readings recorded this
HDL cholesterol
increases, p = 0.008, n = 41
HDL cholesterol, mg/dl | 47±11 | 46±9 | 44±10 | 53±12 *, ° | 0.41 | 0.008
PMID:25148829 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.455
non-significantly increased HDL-C (mean difference = 0.075; 95% CI -0.121, 0.270; P=0.455)
PMID:25379623 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.468
a non-significant decrease in HDL cholesterol (mean difference = -0.051; 95% CI -0.188, 0.086; P = 0.468)
PMID:25379623 · one of two readings recorded this
HDL cholesterol
no effect
High-density cholesterol (HDL, mg/dl) | 47.3 ± 3.5 | 46.5 ± 2.3 | NS | 42.9 ± 2.1 | 46.1 ± 2.6 | NS | 41.8 ± 1.1 | 46.9 ± 2.6 | NS | NS
PMID:26321469 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.56
HDL cholesterol (g/L) | 0.5±0.1 | 0.5±0.2 | 0.63 | 0.6±0.2 | 0.5±0.1 | 0.12 | 0.56
PMID:26406981 · one of two readings recorded this
HDL cholesterol
decreases
In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)
PMID:26700109 · one of two readings recorded this
HDL cholesterol
increases, n = 178
Patients receiving fish oil for more than six months had a modest increase in HDL (5 studies, 178 participants: MD 0.12 mmol/L, 95% CI 0.03 to 0.21; I(2) = 47%) compared to placebo
PMID:27535773 · one of two readings recorded this
HDL cholesterol
no effect, n = 936
There was no change in HDL-cholesterol concentration, but triglyceride concentrations increased by 3.6% in the GTE group, whereas they decreased by 2.5% in the placebo group (P = 0.046)
PMID:27806972 · one of two readings recorded this
HDL cholesterol
increases, p = 0.001
high-density lipoprotein (HDL) (WMD = 3.197 mg dL-1 , 95% CI = 1.455, 4.938, P < 0.001)
PMID:28150351 · one of two readings recorded this
HDL cholesterol
increases
high-density lipoprotein cholesterol (mean difference = 0.039 mmol L-1 ; 95% CI = 0.024-0.054)
PMID:28675488 · one of two readings recorded this
HDL cholesterol
no effect
No changes were observed between treatment arms in HDL-C, triglycerides, fasting plasma glucose (FPG), glycated haemoglobin (HbA1C), waist circumference and body mass index (BMI) levels
PMID:28704936 · one of two readings recorded this
HDL cholesterol
no effect
High-density lipoprotein cholesterol was not significantly different between the 2 groups
PMID:29191850 · one of two readings recorded this
HDL cholesterol
increases, p = 0.001
SMD 0.72; 95% CI, 0.30–1.14, P <.001
PMID:30313075 · one of two readings recorded this
HDL cholesterol
no effect
there was no significant effect on low-density lipoprotein cholesterol (LDL-c), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-c) after L-Arginine treatment
PMID:31442577 · one of two readings recorded this
HDL cholesterol
no effect
HDL-C (mg/dl) | 44.1±3.9 | 44.4±4.2 | 44.6±4.3 | 43.8±3.7 | 44.1±3.9 | 43.7±3.6
PMID:31695332 · one of two readings recorded this
HDL cholesterol
HDL-C (mg/dl) | 44.1±3.9 | 44.4±4.2 | 44.6±4.3 | 43.8±3.7 | 44.1±3.9 | 43.7±3.6
PMID:31695332 · one of two readings recorded this
HDL cholesterol
HDL-C (mg/dl) | 44.1±3.9 | 44.4±4.2 | 44.6±4.3 | 43.8±3.7 | 44.1±3.9 | 43.7±3.6
PMID:31695332 · one of two readings recorded this
HDL cholesterol
increases
modest increases in HDL were observed in trials that used DHA as a supplement (0.161 mmol l-1; 95% CI 0.017, 0.304)
PMID:32175534 · one of two readings recorded this
HDL cholesterol
no effect
but not in trials using EPA (0.040 mmol l-1; 95% CI -0.132, 0.212)
PMID:32175534 · one of two readings recorded this
HDL cholesterol
increases
high-density lipoprotein (HDL) (WMD 0.033 mmol l-1; 95% CI 0.004, 0.062)
PMID:32175534 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
HDL cholesterol level was higher among Asian and low-dose(< 2 g/d n-3 PUFA) subgroups compared to their counterparts (p < 0.05)
PMID:32384902 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
HDL cholesterol level was higher among Asian and low-dose(< 2 g/d n-3 PUFA) subgroups compared to their counterparts (p < 0.05)
PMID:32384902 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
an increase of high density lipoprotein (HDL) cholesterol level by 0.21 (95%CI: 0.05 to 0.37, p < 0.05)
PMID:32384902 · one of two readings recorded this
HDL cholesterol
no effect
there were no significant differences between lycopene intervention and control groups for blood pressure and lipids (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides)
PMID:32652029 · one of two readings recorded this
HDL cholesterol
no effect
There was no effect of zinc supplementation on HDL cholesterol for either low- or high-dose supplementation
PMID:32722790 · one of two readings recorded this
HDL cholesterol
increases, WMD: 1.473 mg/dl, 95% CI: 0.319-2.627, p = 0.012
We did observe an overall increase in HDL-C (WMD: 1.473 mg/dl, 95 % CI: 0.319-2.627, p = 0.012).
PMID:32755613 · one of two readings recorded this
HDL cholesterol
increases, p = 0.0007, n = 252
HDLc levels were significantly increased by 1.66 mg/dL in the high-dose groups (95% CI: 0.70, 2.61; I2 = 40%; p = 0.0007; four RCTs; n = 252)
PMID:32932644 · one of two readings recorded this
HDL cholesterol
no effect
Non-significant results were found for the levels of FBS, TG, and HDLc in the low-dose groups
PMID:32932644 · one of two readings recorded this
HDL cholesterol
increases, p = 0.0006, n = 125
meta-analysis of two studies revealed a significant HDLc-increasing effect of L-carnitine when compared with the control groups (subtotal MD = 3.50, 95% CI: 1.50 to 5.47, I2 = 0%, p = 0.0006, two RCTs, n = 125)
PMID:32932644 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
increased HDLc in the Italian group (subtotal MD = 1.85, 95% CI: 0.04 to 3.66, I2 = 54%, p = 0.05)
PMID:32932644 · one of two readings recorded this
HDL cholesterol
no effect
Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups
PMID:32932644 · one of two readings recorded this
HDL cholesterol
no effect
The analysis did not show statistically significant differences (Table 2,.
PMID:33514002 · one of two readings recorded this
HDL cholesterol
increases
high density lipoprotein-cholesterol (HDL-C) (WMD = 0.07 mmol/L; 95% CI, 0.04, 0.09 mmol/L)
PMID:34229258 · one of two readings recorded this
HDL cholesterol
increases, p = 0.01
an increase in HDL cholesterol levels (p = 0.01)
PMID:34959992 · one of two readings recorded this
HDL cholesterol
decreases, n = 7
HDL-C | Type of disease | 7 | Obesity | –0.22 | [–0.43, –0.01] | 87 | 81.3
PMID:35431994 · one of two readings recorded this
HDL cholesterol
no effect, n = 5
5 | Other | –0.22 | [–0.47, 0.03] | 81
PMID:35431994 · one of two readings recorded this
HDL cholesterol
no effect, n = 3
3 | T2DM | 0.05 | [-0.26, 0.36] | 0
PMID:35431994 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.03
There was a significant decrease following RSV administration in WC with an SMD of –0.36 (95% CI: –0.59 to –0.14; P = 0.002; I2 = 88%), hemoglobin A1c (HbA1c): –0.48 (–0.69 to –0.2; P ≤ 0.001; I2 = 94%), TC: –0.15 (–0.3 to –0.01; P = 0.003; I2 = 94%), low-density lipoprotein cholesterol (LDL-C): –0.42 (–0.57 to –0.27; P ≤ 0.001; I2 = 92%), and HDL-C:0.16 (–0.31 to –0.02; P = 0.03; I2 = 81%).
PMID:35431994 · one of two readings recorded this
HDL cholesterol
p = 0.1
HDL-c, mg/dL | 42.49 ± 7.9 | 45.83 ± 9.0 | 0.1
PMID:35538431 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.4
no differences were detected between groups for HDL cholesterol (P = 0.4) and triglycerides (P = 0.8)
PMID:35575618 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.001
HDL cholesterol (mmol/L), median (IQR) | 0.9 (0.4–1.2) | 1.2 (1.0–1.4) | <.001
PMID:35585781 · one of two readings recorded this
HDL cholesterol
no effect
MD, −0.20 mmol/L; CI: −0.56 to 0.16
PMID:36008064 · one of two readings recorded this
HDL cholesterol
increases
MD, 0.10 mmol/L; 95% CI: 0.01 to 0.20
PMID:36008064 · one of two readings recorded this
HDL cholesterol
no effect
MD, 0.10 mmol/L; CI: 0.10 to 0.30
PMID:36008064 · one of two readings recorded this
HDL cholesterol
no effect
MD, 0.00 mmol/L; CI: −0.36 to 0.36
PMID:36008064 · one of two readings recorded this
HDL cholesterol
no effect
MD, −0.20 mmol/L; CI: −0.60 to 0.20
PMID:36008064 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
significant decrease in FBG, insulin, HbA1c, HOMO-IR, LDL-c, TG, VLDL, CHOL, LDL-c.HDL-c ratio, AIP, IL-6, and MDA and a significant increase in HDL-c, QUICKI index, BDNF, and TAC compared with the initial value (p for all <.05)
PMID:36101997 · one of two readings recorded this
HDL cholesterol
QP mean difference 1.0 ± 4.5 mg/dL (within-group), p = 0.43, n = 22
Furthermore, there was a significant improvement only in the CP group in HDL-c (mean difference of CP: 10.0 ± 5.3, QP: 1.0 ± 4.5, CQ: 1.8 ± 4.6, DP: 0.9 ± 6.9; P < 0.001) (Table 3).
PMID:36192751 · one of two readings recorded this
HDL cholesterol
Not recorded as a finding: One-sided negation ('does not significantly improve') does not establish no_effect (rule 1a).
This meta-analysis showed that selenium supplementation has a positive effect on TAC, and supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG.
PMID:36740666 · one of two readings recorded this
HDL cholesterol
no effect
supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG
PMID:36740666 · one of two readings recorded this
HDL cholesterol
no effect
no differences were found between groups in improving HDL-C and IL-6 levels
PMID:36805484 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.3
high-density lipoprotein cholesterol (HDL-C) (SMD, 0.55; 95% CI, -0.48 to 1.57; p = 0.30; I2 = 96%)
PMID:36805484 · one of two readings recorded this
HDL cholesterol
no effect
the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (- 0.07 mmol/L, 95% CI - 0.16 to 0.02)
PMID:36941490 · one of two readings recorded this
HDL cholesterol
increases
the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (- 0.07 mmol/L, 95% CI - 0.16 to 0.02)
PMID:36941490 · one of two readings recorded this
HDL cholesterol
increases, n = 1471
Berberine increased HDL cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.11, 15 studies, n = 1471)
PMID:36941490 · one of two readings recorded this
HDL cholesterol
no effect
HDL (MD 1.38 mg/dL [95%CI: -1.27 to 4.03])
PMID:37183391 · one of two readings recorded this
HDL cholesterol
increases
raising HDL (MD 1.97 mg/dL [95%CI: 1.16 to 2.78])
PMID:37183391 · one of two readings recorded this
HDL cholesterol
increases
2.31 mg/dL (95% CI: 0.48, 4.14)
PMID:37604307 · one of two readings recorded this
HDL cholesterol
increases
4.48 mg/dL (95% CI: 2, 6.97)
PMID:37604307 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.188
dosage: Pnonlinearity = 0.188
PMID:37604307 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.406
duration: Pnonlinearity = 0.406
PMID:37604307 · one of two readings recorded this
HDL cholesterol
no effect
age >60 y: WMD: 0.86; 95% CI: −0.03, 1.76
PMID:37604307 · one of two readings recorded this
HDL cholesterol
no effect
female: WMD: 0.00; 95% CI: −1.07, 1.07
PMID:37604307 · one of two readings recorded this
HDL cholesterol
increases, p = 0.003
A significant elevation in serum concentrations of HDL was seen after zinc supplementation (WMD: 3.76; 95% CI: 1.30, 6.22; P = 0.003)
PMID:37604307 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.026, n = 14
HDL, mmol/l | 1.14±0.08 | 1.20±0.09 | 0.026
PMID:37922013 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.32
HDL Cholesterol, mg/dL b | 56.5 ± 14.2 | 57.6 ± 16.1 | 0.32
PMID:38110301 · one of two readings recorded this
HDL cholesterol
no effect, SMD=0.31, 95% CI -0.60 to 1.22, p = 0.51
Both low-density lipoprotein (LDL) (mmol/L) (SMD=-0.34, 95%CI [-0.73, 0.04], P=0.08) and high-density lipoprotein (HDL) (mmol/L) (SMD=0.31, 95%CI [-0.60, 1.22], P=0.51) showed no difference compared to the GKB and control groups.
PMID:38264278 · one of two readings recorded this
HDL cholesterol
no effect
HDL (WMD: −0⋅03 mg/dl, 95 % CI: −1⋅23, 1⋅17, P = 0⋅960)
PMID:38282652 · one of two readings recorded this
HDL cholesterol
increases
fish oil supplements had a positive and significant effect on HDL (WMD: 2.54 mg/dl, 95% CI: 0.55, 4.52)
PMID:38317191 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.25
HDL-C (MD = −0.02; 95% CI: −0.05, 0.01; peffect = 0.25)
PMID:38542695 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
Also significant improvement (p<0.05) was noted for high density lipoprotein (HDL) levels (20.1% to 57.4%) in group B after completion of study
PMID:39460970 · one of two readings recorded this
HDL Cholesterol
increases, n = 15
HDL Cholesterol | PLA | 15 | 48.3 ± 7.8 | 53.4 ± 8.3† | 50.9 ± 2.2 | T | 0.000 | 0.862
PMID:39568140 · one of two readings recorded this
HDL Cholesterol
no effect, p = 0.724, n = 15
(mg/dL) | AX | 15 | 47.1 ± 8.4 | 51.9 ± 9.3† | 49.5 ± 2.2 | G x T | 0.724 | 0.005
PMID:39568140 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.12
(SMD: 0.15, 95% CI: −0.04 to 0.35, p = 0.12)
PMID:39723101 · one of two readings recorded this
HDL cholesterol
increases, p = 0.05
(SMD: 0.28, 95% CI: 0.00 to 0.56, p = 0.05)
PMID:39723101 · one of two readings recorded this
HDL cholesterol
no effect, n = 113
The high-density lipoprotein cholesterol level remained unchanged from baseline across all treatment groups.
PMID:40029660 · one of two readings recorded this
HDL cholesterol
no effect
In rats treated with Laurus nobilis and Beta vulgaris, all biochemical parameters-excluding HDL-were significantly decreased compared to the hyperuricemia model rats (P ≤ 0.01).
PMID:40292062 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.63
HDL | Curcumin | 33.12 ± 9.62 | 32.12 ± 6.47 | 0.23 | − 0.99 ± 4.76 | − 0.65 ± 1.37 (− 3.41, 2.10) | 0.63
PMID:40514680 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.84
Placebo | 32.84 ± 11.14 | 32.56 ± 9.00 | 0.84 | − 0.27 ± 8.29
PMID:40514680 · one of two readings recorded this
HDL cholesterol
no effect, WMD 0.60, 95% CI -0.16 to 1.35, p = 0.12
The meta-analysis of HDL levels included 13 RCTs which demonstrated no clinical and statistical effect of Mg supplementation on HDL levels (WMD = 0.60, 95% CI: –0.16 to 1.35; P = 0.12).
PMID:40641714 · one of two readings recorded this
HDL cholesterol
no effect, OR = -0.13, 95% CI -0.37 to 0.10, p = 0.257
For HDL (6 studies), no significant effect was observed (OR = -0.13, 95% CI [− 0.37, 0.10], p = 0.257) with low heterogeneity (Fig. C, I2 = 0.0%, p = 0.934).
PMID:40705097 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.95
HDL cholesterol (MD -0.15; 95%CI -5.25 to 4.97; p = 0.95; I2 = 0%)
PMID:41022489 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.05
Fig. 9 shows the selenium supplementation could not significantly increase HDL-C levels in patients, which was beneficial for their lipid control(P = 0.05, MD = 3.78, 95% CI: −0.04, 7.61)
PMID:41073938 · one of two readings recorded this
HDL cholesterol
no effect, SMD 0.18 (95% CI -0.60 to 0.96), p = 0.65, n = 325
No significant effect was found (SMD: 0.18, 95% CI: −0.60 to 0.96, p = 0.65; I2 = 90%).
PMID:41305552 · one of two readings recorded this
HDL cholesterol
decreases, SMD = -0.19, 95% CI: -0.37 to -0.01, p = 0.04, n = 480
The results indicated that, compared to placebo, mineral supplements significantly reduced HDL levels in PCOS patients (SMD = -0.19, 95% CI: -0.37 to -0.01, p = 0.04).
PMID:41580698 · one of two readings recorded this
HDL cholesterol
decreases, SMD = -0.19, 95% CI: -0.37 to -0.01, p = 0.04, p = 0.04, n = 480
The results indicated that, compared to placebo, mineral supplements significantly reduced HDL levels in PCOS patients (SMD = -0.19, 95% CI: -0.37 to -0.01, p = 0.04).
PMID:41580698 · one of two readings recorded this
HDL cholesterol
no effect, SMD -0.158, 95% CI -0.253 to -0.062, p = 0.902
In contrast, no significant changes were detected in HDL levels D; SMD: −0.158, 95%CI=−0.253 to −0.062; I²<0.001%, p=0.902).
PMID:41760304 · one of two readings recorded this
HDL cholesterol
no effect
Throughout the 24-week intervention, lipid profiles, including total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol, remained stable and within normal reference ranges in both the placebo and probiotic groups, with no statistically significant differences observed between groups
PMID:42124006 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.0015
significant decreases were observed at week 5 (from 69.00 ± 16.48 to 55.33 ± 13.29, 20% reduction from the baseline to week 5, p = 0.0015)
PMID:42197276 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.015
week 9 (from 69.00 ± 16.48 to 57.82 ± 16.01, 16.2% reduction from the baseline to week 9, p = 0.015)
PMID:42197276 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.04
Significant reductions were observed in the placebo group at week 5 (from 55.70 ± 12.59 to 49.50 ± 9.62, 11% reduction from the baseline, p = 0.04)
PMID:42197276 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.376, n = 47
HDL cholesterol (mmol/L) | 47 | 1.5 (1.4) | 1.4 (0.3) | −0.1 [−0.5 to 0.3] | 0.376
PMID:42420793 · one of two readings recorded this
HDL cholesterol
increases, p = 0.028
However, there was a significant rise within the NAC group with respect to HDL-C (p = 0.028)
PMID:42587287 · one of two readings recorded this
HDL cholesterol
increases, WMD 1.45 mg/dL, 95% CI 0.37 to 2.54
HDL-C levels significantly increased following Mg supplementation (WMD: 1.45 mg/dL, 95% CI: 0.37, 2.54).
PMID:42588058 · one of two readings recorded this
HDL cholesterol
no effect, p = 0.07
No significant differences were observed (MD = 2.67; 95% CI −0.24 to 5.59; p = 0.07)
PMID:42594341 · one of two readings recorded this
HDL cholesterol
increases, p = 0.014
HDL | 0.0502 [0.0101 – 0.0904] | 0.014 | 0.0136 [-0.0029 – 0.0301] | 0.107 | -0.1858 [-0.2251 – -0.1465] | <0.001
PMID:42802824 · one of two readings recorded this
HDL cholesterol
increases, p = 0.007
HDL | 0.0604 [0.0164 – 0.1045] | 0.007 | 0.0170 [0.0001 – 0.0339] | 0.048
PMID:42802824 · one of two readings recorded this
HDL cholesterol
p = 0.05
HDL (mmol/L) | 1.08 (0.28) | 1.13 (0.26) | 0.050
PMID:42802824 · one of two readings recorded this
Sources cited
37 papers
- Subject
- hdl cholesterol
- Findings
- 37
- Papers
- 37
Efficacy of Vitamin E on Lipid Profile in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.record2026PMID:420927481 finding
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.record2026PMID:425143201 finding
Safety of Lactiplantibacillus plantarum K014 in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.record2026PMID:421240061 finding
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.record2025PMID:401804161 finding
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.record2025PMID:415152491 finding
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk.record2025PMID:407599971 finding
Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients.record2025PMID:406764001 finding
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.record2024PMID:382329061 finding
Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.record2024PMID:379220131 finding
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.record2024PMID:387551421 finding
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.record2023PMID:370378911 finding
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.record2023PMID:373337861 finding
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.record2023PMID:357516251 finding
A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease.record2022PMID:337828201 finding
Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis.record2022PMID:360587631 finding
Effect of oral magnesium supplement on cardiometabolic markers in people with prediabetes: a double blind randomized controlled clinical trial.record2022PMID:363074271 finding
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.record2022PMID:356856021 finding
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.record2021PMID:345167031 finding
Effects of Dose and Duration of Zinc Interventions on Risk Factors for Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta-Analysis.record2021PMID:327227901 finding
The Effects of Magnesium Supplementation on Lipid Profile Among Type 2 Diabetes Patients: a Systematic Review and Meta-analysis of Randomized Controlled Trials.record2021PMID:324682241 finding
The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.record2020PMID:329517481 finding
The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.record2020PMID:327556131 finding
Effect of L-Arginine supplementation on lipid profiles and inflammatory markers: A systematic review and meta-analysis of randomized controlled trials.record2019PMID:314425771 finding
The effect of melatonin supplementation on lipid profile and anthropometric indices: A systematic review and meta-analysis of clinical trials.record2019PMID:312351131 finding
Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.record2018PMID:292914291 finding
Effects of dietary pectin on the profile and transport of intestinal bile acids in young pigs.record2018PMID:301023771 finding
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.record2018PMID:304669861 finding
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.record2018PMID:304177821 finding
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.record2018PMID:301561451 finding
Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial.record2016PMID:267001091 finding
Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials.record2016PMID:267540581 finding
Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis.record2015PMID:259137561 finding
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.record2014PMID:254744841 finding
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.record2013PMID:226108531 finding
Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus.record2011PMID:206341741 finding
Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias.record2009PMID:198384891 finding
Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.record2006PMID:169783671 finding